BMS Signs an Exclusive Option to License Agreement with Dragonfly Therapeutics to Develop Novel Therapies for Multiple Sclerosis and Neuro-inflammation Targets

 BMS Signs an Exclusive Option to License Agreement with Dragonfly Therapeutics to Develop Novel Therapies for Multiple Sclerosis and Neuro-inflammation Targets

Bristol-Myers (BMS) Reports Results of Opdivo (nivolumab) + Yervoy (ipilimumab) in P-II CheckMate -650 trial for Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Shots:

  • Dragonfly to receive $55M upfront, additional payments for development, regulatory and sales milestones plus royalties on sales of approved products. BMS to get exclusive option to license exclusive worldwide IPR for multiple candidates developed using Dragonfly’s platform for multiple new targets
  • The focus of the agreement is to expand the collaboration b/w the companies from oncology and autoimmune diseases to develop drug candidates against multiple targets including multiple sclerosis and neuroinflammation
  • Dragonfly’s TriNKET technology immunotherapy provides the active connection between cancer cells, and cells of the immune system including NK cells, T cells, B cells that help attack and kill cancer

Click here to read full press release/ article | Ref: PRNewswire | Image: Behance

Shiwani Sharma

Shiwani Sharma was Senior Editor at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post